Granted Patent
B2
US 10,251,892 · App. 15/627,665 · Granted Apr 9, 2019
Bicyclic heterocycles as FGFR4 inhibitors
View Patent ↗
Loading inventors, assignments & file history…
Abstract
The present disclosure relates to bicyclic heterocycles of Formula (I′), and pharmaceutical compositions of the same, that are inhibitors of the FGFR3 and/or FGFR4 enzyme and are useful in the treatment of FGFR-associated diseases.
Claims (2)
1. A method for treating bladder cancer in a patient, said method comprising: administering to said patient in need thereof a therapeutically effective amount of a compound, which is 3-(2,6-difluoro-3,5-dimethoxyphenyl)-7-(1,3-dimethyl-1H-pyrazol-4-yl)-1-pyrimidin-4-yl-3,4-dihydropyrido[4,3-d]pyrimidin-2(1H)-one
or a pharmaceutically acceptable salt thereof.
Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Nov 10, 2021
From: INCYTE CORPORATION
To: INCYTE CORPORATION; INCYTE HOLDINGS CORPORATION
Reel/Frame 058815/0857 →
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Jun 20, 2017
From: LU, LIANG; SHEN, BO; SOKOLSKY, ALEXANDER; WANG, XIAOZHAO; WU, LIANGXING; YAO, WENQING; YE, YINGDA
To: INCYTE CORPORATION
Reel/Frame 042757/0015 →
Cited By (5)